Ensuring Quality of Life in Chronic Myeloid Leukemia Populations

Commentary
Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.

When assessing a treatment course for patients with chronic myeloid leukemia (CML), clinicians should aim to maintain long-term patient quality of life by limiting the number of symptoms and adverse effects (AEs) they have during their therapy, according to Claire Saxton, MBA.

Saxton, the executive vice president of Insights and Impact at Cancer Support Community, spoke with CancerNetwork® at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting about what patients with CML should expect in terms of communication and potential toxicity during their therapy.

Saxton highlighted how patients should openly communicate with their providers about any toxicities that may impact their quality of life during treatment. For example, patients should inform their treatment team about any experiences related to AEs such as fatigue or diarrhea, which can affect their ability to participate in personal activities or use public transportation.

According to Saxton, discussing these toxicities allows providers to better understand the patient’s perspective on how much their daily routine changes due to treatment for CML. As a result of these conversations, providers may then be able to adjust the treatment course to help improve patient’s quality of life.

Transcript:

In the long term, the treatment journey is [about] keeping [patients from] having as few symptoms and AEs and [ensuring] as good a quality of life as possible. [Patients should] be clear with [their] treatment team: "My fatigue means that I can’t do some of my favorite things. The fact that I have diarrhea means that I can’t take the bus to work anymore."

When [patients] put things in the perspective of how [CML is] affecting [their] everyday life, the treatment team will be much better able to make sure that whatever treatment that [they are] on is the one that is giving [them] the best quality of life.

Recent Videos
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Related Content
Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

American Society for Transplantation and Cellular Therapy
November 24th 2025
Article

Researchers have observed that HSC–derived innate lymphoid cells prevent GVHD by inducing interleukin 9 driven T-cell senescence.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

According to Toru Kondo, PhD, EVA1-ADC is able to target glioblastoma-initiating cells while sparing normal cells and stem cells during treatment.

Will Targeting EVA1 With ADCs Eliminate Glioblastoma-Initiating Cells?

Tim Cortese
November 16th 2025
Article

According to Toru Kondo, PhD, EVA1-ADC is able to target glioblastoma-initiating cells while sparing normal cells and stem cells during treatment.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC

Russ Conroy
November 15th 2025
Article

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

Although the study was underpowered due to a small sample size, non-significant improvements in functional and social well-being occurred with MOST-S26.

Nurse-Led Telehealth Displays Feasibility in Ovarian Cancer Follow-Up

Roman Fabbricatore
November 14th 2025
Article

Although the study was underpowered due to a small sample size, nonsignificant improvements in functional and social well-being occurred with MOST-S26.